{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T01:03:18Z","timestamp":1779757398787,"version":"3.53.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2027649"],"award-info":[{"award-number":["2027649"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2027569"],"award-info":[{"award-number":["2027569"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-026-03155-9","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:36:19Z","timestamp":1775738179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An LNP antiviral siRNA drug cocktail delivered intranasally is effective against a range of respiratory viruses"],"prefix":"10.1186","volume":"23","author":[{"given":"Victor Baba","family":"Oti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tufael","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruba","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Wales-Earl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel AJ","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"3155_CR1","doi-asserted-by":"publisher","first-page":"106024","DOI":"10.1016\/j.antiviral.2024.106024","volume":"232","author":"T Chokwassanasakulkit","year":"2024","unstructured":"Chokwassanasakulkit T, et al. SiRNAs as antiviral drugs \u2013 Current status, therapeutic potential and challenges. Antiviral Res. 2024;232:106024.","journal-title":"Antiviral Res"},{"key":"3155_CR2","doi-asserted-by":"crossref","unstructured":"Supramaniam A, et al. Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection. Journal of Microbiology, Immunology and Infection; 2023.","DOI":"10.1016\/j.jmii.2023.02.010"},{"issue":"1","key":"3155_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nm1164","volume":"11","author":"V Bitko","year":"2005","unstructured":"Bitko V, et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2005;11(1):50\u20135.","journal-title":"Nat Med"},{"issue":"23","key":"3155_CR4","doi-asserted-by":"publisher","first-page":"8682","DOI":"10.1073\/pnas.0402630101","volume":"101","author":"SM Tompkins","year":"2004","unstructured":"Tompkins SM, et al. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A. 2004;101(23):8682\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3155_CR5","doi-asserted-by":"publisher","first-page":"105815","DOI":"10.1016\/j.antiviral.2024.105815","volume":"222","author":"A Idris","year":"2024","unstructured":"Idris A, et al. An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity. Antiviral Res. 2024;222:105815.","journal-title":"Antiviral Res"},{"issue":"9","key":"3155_CR6","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1111\/all.14850","volume":"76","author":"M Khaitov","year":"2021","unstructured":"Khaitov M, et al. Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation. Allergy. 2021;76(9):2840\u201354.","journal-title":"Allergy"},{"key":"3155_CR7","doi-asserted-by":"crossref","unstructured":"Chang Y-C et al. A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. EMBO Molecular Medicine. 2022; n\/a(n\/a): p. e15298.","DOI":"10.15252\/emmm.202115298"},{"issue":"11","key":"3155_CR8","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1007\/s13346-025-01815-x","volume":"15","author":"YM Idres","year":"2025","unstructured":"Idres YM, Idris A, Gao W. Preclinical testing of antiviral siRNA therapeutics delivered in lipid nanoparticles in animal models - a comprehensive review. Drug Deliv Transl Res. 2025;15(11):3899\u2013916.","journal-title":"Drug Deliv Transl Res"},{"key":"3155_CR9","doi-asserted-by":"crossref","unstructured":"Liang W et al. Pulmonary Delivery Biol Drugs Pharm, 2020;12(11):1025.","DOI":"10.3390\/pharmaceutics12111025"},{"key":"3155_CR10","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1038\/mtna.2013.22","volume":"2","author":"J McCaskill","year":"2013","unstructured":"McCaskill J, et al. Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA. Mol Ther Nucleic Acids. 2013;2:e96.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3155_CR11","doi-asserted-by":"crossref","unstructured":"Idris A et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther. 2021;29(7):2219-2226.","DOI":"10.1016\/j.ymthe.2021.05.004"},{"issue":"31","key":"3155_CR12","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1016\/j.vaccine.2022.05.077","volume":"40","author":"MP Nowalk","year":"2022","unstructured":"Nowalk MP, et al. Estimating the burden of adult hospitalized RSV infection including special populations. Vaccine. 2022;40(31):4121\u20137.","journal-title":"Vaccine"},{"issue":"10127","key":"3155_CR13","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano AD, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285\u2013300.","journal-title":"Lancet"},{"issue":"10334","key":"3155_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/S0140-6736(22)00383-X","volume":"399","author":"MC Swets","year":"2022","unstructured":"Swets MC, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022;399(10334):1463\u20134.","journal-title":"Lancet"},{"key":"3155_CR15","doi-asserted-by":"publisher","first-page":"101477","DOI":"10.1016\/j.coviro.2025.101477","volume":"73","author":"CE Ruckel","year":"2025","unstructured":"Ruckel CE, Wolf JD, Plemper RK. Status of advanced respiratory syncytial virus antiviral therapeutics 2025. Curr Opin Virol. 2025;73:101477.","journal-title":"Curr Opin Virol"},{"issue":"20","key":"3155_CR16","doi-asserted-by":"publisher","first-page":"12244","DOI":"10.3390\/ijms232012244","volume":"23","author":"JM Smyk","year":"2022","unstructured":"Smyk JM, et al. Evolution of Influenza Viruses\u2014Drug Resistance, Treatment Options, and Prospects. Int J Mol Sci. 2022;23(20):12244.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3155_CR17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/microorganisms11051095","volume":"11","author":"A Saim-Mamoun","year":"2023","unstructured":"Saim-Mamoun A, et al. Viral Fitness of Baloxavir-Resistant Recombinant Influenza B\/Victoria- and B\/Yamagata-like Viruses Harboring the I38T PA Change, In Vitro, Ex Vivo and in Guinea Pigs. Microorganisms. 2023;11(5):1095.","journal-title":"Microorganisms"},{"key":"3155_CR18","doi-asserted-by":"crossref","unstructured":"Akerman A et al. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. eBioMedicine. 2023;90:104545.","DOI":"10.1016\/j.ebiom.2023.104545"},{"issue":"11","key":"3155_CR19","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1007\/s13346-023-01361-4","volume":"13","author":"A Kaushal","year":"2023","unstructured":"Kaushal A. Innate immune regulations and various siRNA modalities. Drug Deliv Transl Res. 2023;13(11):2704\u201318.","journal-title":"Drug Deliv Transl Res"},{"key":"3155_CR20","doi-asserted-by":"crossref","unstructured":"Anglero-Rodriguez YI et al. High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination. Nucleic Acids Res. 2025;53(1):gkae1195.","DOI":"10.1093\/nar\/gkae1195"},{"issue":"6","key":"3155_CR21","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1128\/JVI.02035-07","volume":"82","author":"KJ von Eije","year":"2008","unstructured":"von Eije KJ, Brake Oter, Berkhout B. Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol. 2008;82(6):2895\u2013903.","journal-title":"J Virol"},{"issue":"7","key":"3155_CR22","doi-asserted-by":"publisher","first-page":"e0159211","DOI":"10.1371\/journal.pone.0159211","volume":"11","author":"M ElHefnawi","year":"2016","unstructured":"ElHefnawi M, et al. Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes. PLoS ONE. 2016;11(7):e0159211.","journal-title":"PLoS ONE"},{"issue":"5","key":"3155_CR23","first-page":"284","volume":"38","author":"D Cipolla","year":"2025","unstructured":"Cipolla D, et al. Inhalable and Nasal Biologics: Analytical, Formulation, Development, and Regulatory Considerations. J Aerosol Med Pulmonary Drug Delivery. 2025;38(5):284\u2013303.","journal-title":"J Aerosol Med Pulmonary Drug Delivery"},{"issue":"2","key":"3155_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.healun.2015.08.012","volume":"35","author":"J Gottlieb","year":"2016","unstructured":"Gottlieb J, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transpl. 2016;35(2):213\u201321.","journal-title":"J Heart Lung Transpl"},{"key":"3155_CR25","doi-asserted-by":"publisher","first-page":"8085","DOI":"10.2147\/IJN.S517385","volume":"20","author":"Y Tayyar","year":"2025","unstructured":"Tayyar Y, Idris A, Yassine H. Intranasal and Pulmonary Lipid Nanoparticles for Gene Delivery: Turning Challenges into Opportunities. Int J Nanomed. 2025;20:8085\u201399.","journal-title":"Int J Nanomed"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03155-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:36:10Z","timestamp":1779755770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03155-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3155"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03155-9","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in compliance with relevant laws and institutional guidelines and in accordance with the ethical standards of the Declaration of Helsinki. All work was approved by the Griffith University Animal Ethics Committee (Animal ethics approval: MHIQ\/14\/21\/AEC), Queensland University of Technology and the Queensland Institute of Medical Research Animal Ethics Committees (P3866, A2304-603 (QIMR) and AE AdRev 2023-7413-14668 (QUT)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"A.I is a Director of Research for Intelligene Pty Ltd and holds shares in the company. N.A.J.M is a consultant for Prorenata Biotech.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}